HUMA

Company Overview — What Does Humacyte, Inc. Do?

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte, Inc. (HUMA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Laura E. Niklason and employs approximately 150 people. With a market capitalization of $131M, HUMA is one of the notable companies in the Healthcare sector.

Humacyte, Inc. (HUMA) Stock Rating — Avoid (April 2026)

As of April 2026, Humacyte, Inc. receives a Avoid rating with a composite score of 14.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.HUMA ranks #4,355 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Humacyte, Inc. ranks #803 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HUMA Stock Price and 52-Week Range

Humacyte, Inc. (HUMA) currently trades at $0.67. The stock gained $0.06 (10.2%) in the most recent trading session. The 52-week high for HUMA is $3.36, which means the stock is currently trading -80.1% from its annual peak. The 52-week low is $0.88, putting the stock -24.0% above its annual trough. Recent trading volume was 4.7M shares, reflecting moderate market activity.

Is HUMA Overvalued or Undervalued? — Valuation Analysis

Humacyte, Inc. (HUMA) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 43.34x, versus the sector average of 2.75x. The price-to-sales ratio is 85.77x, compared to 1.66x for the average Healthcare stock.

At current multiples, Humacyte, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Humacyte, Inc. Profitability — ROE, Margins, and Quality Score

Humacyte, Inc. (HUMA) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1776.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -47.5% versus the sector average of -33.1%.

On a margin basis, Humacyte, Inc. reports gross margins of 55.4%, compared to 71.5% for the sector. The operating margin is -5866.5% (sector: -66.1%). Net profit margin stands at -2422.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HUMA Debt, Balance Sheet, and Financial Health

Humacyte, Inc. has a debt-to-equity ratio of 1140.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.69x, indicating strong short-term liquidity. Total debt on the balance sheet is $35M. Cash and equivalents stand at $19M.

HUMA has a beta of 2.42, meaning it is more volatile than the broader market — a $10,000 investment in HUMA would be expected to move 142.4% more than the S&P 500 on any given day. The stability factor score for Humacyte, Inc. is 12/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Humacyte, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Humacyte, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-55M. Gross margin was 55.4%. Operating income came in at $-108M.

In FY 2025, Humacyte, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-41M. Gross margin was -376.1%. Operating income came in at $-108M.

In Q3 2025, Humacyte, Inc. reported revenue of $753,000 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-18M. Gross margin was 65.5%. Operating income came in at $-24M.

In Q2 2025, Humacyte, Inc. reported revenue of $301,000 and earnings per share (EPS) of $-0.24. Net income for the quarter was $-38M. Gross margin was 29.2%. Operating income came in at $-30M.

Over the past 8 quarters, Humacyte, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $2M. Investors analyzing HUMA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HUMA Dividend Yield and Income Analysis

Humacyte, Inc. (HUMA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HUMA Momentum and Technical Analysis Profile

Humacyte, Inc. (HUMA) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 36/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

HUMA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Humacyte, Inc. (HUMA) ranks #803 out of 838 stocks based on the Blank Capital composite score. This places HUMA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HUMA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HUMA vs S&P 500 (SPY) comparison to assess how Humacyte, Inc. stacks up against the broader market across all factor dimensions.

HUMA Next Earnings Date

No upcoming earnings date has been announced for Humacyte, Inc. (HUMA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HUMA? — Investment Thesis Summary

The quantitative profile for Humacyte, Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 12/100) increases portfolio risk.

In summary, Humacyte, Inc. (HUMA) earns a Avoid rating with a composite score of 14.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HUMA stock.

Related Resources for HUMA Investors

Explore more research and tools: HUMA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HUMA head-to-head with peers: HUMA vs AZN, HUMA vs SLGL, HUMA vs VMD.